A research perspective published in eLife identifies a far longer technique for testing stem cell survival. See the Perspective for Kelsey Coyne Diamond Tarmoen and colleagues.

The goal of stem cell testing involves collecting and comparing newborn neurons derived from adult donors. Researchers have since been able to demonstrate widespread support for the growth of damaged newborn neurons and its subsequent ability to regenerate-and to investigate the ability of different brain regions to repair themselves from the damaged cell.

Coyne et al. demonstrated that neuron recovery can be induced at a high level after a single dose of an experimental gene therapy regimen containing the stem cell-Deep-Brain-V1 gene. The researchers would then test whether the treatment produced the beneficial effects on the hippocampal formation emotion-related functions and cognitive skills typical with aging.

We proved through brain transcriptome profiling and deep-brain read-out that we can replenish synaptic branches from newly formed adult brain neurons by introducing exactly the donor cells maintaining their viability and providing them back to the growing population of developing neural progenitors. Upon the reintroduction of the adult stem cells we see neuronal growth and performance resembling that of a second- or third-phase re-growing brain says Coyne.

Experimental gene therapy sparing adult stem cells.

To address the challenge posed by the newly found adult stem cells researchers added a common element: allowing the required adult stem cells to mature before they can be taken up by non-neuronal cells.

The regenerative salience of adult neural stem cell candidates in the adult brain in pathological conditions pose a major hurdle in research efforts introduces Vera Terzic a stem cell researcher at CMMI and University of Cambridge UK and lead author of the paper.

But if successful gene therapy for neurogenesis is confirmed in a large population of neuroimmune-challenged patients it will provide a potent tool to overcome intense efforts to make the adult stem cells in a comorbid environment revert back to their embryonic and fetal forms as a therapeutic solution during neurorejuvenation and neuroic disorders associated with vascular endothelial growth and myeloid growth such as multiples cerebral ischemia multiple sclerosis and folate deficiency she concludes.